Loading stock data…
IRTC
$120.80-8.36 (-6.47%)
Market ClosedLast close May 1
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
iRhythm Holdings, Inc. in the Healthcare sector is trading at $120.80. The stock is currently near its 52-week low of $112.31, remaining 23.2% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why IRTC maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$120.80
Potential Upside
5%
Whystock Fair Value$126.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$191.14+58.2%
Range$147.00 – $254.00
Fundamentals
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.99B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.51%
Volume
Today's trading volume
1.32M
Recent News
IRTC Q1 Deep Dive: Market Expansion and Margin Gains Amid Regulatory and AI Developments
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 25.7% year on year to $199.4 million. The company expects the full year’s revenue to be around $880 million, close to analysts’ estimates. Its non-GAAP loss of $0.35 per share was 45.3% above analysts’ consensus estimates.
iRhythm Technologies, Inc. Q1 2026 Earnings Call Summary
Moby summary of iRhythm Technologies, Inc.'s Q1 2026 earnings call
Truist Cuts PT on iRhythm Technologies (IRTC) as Part of Fiscal Q1 Results Preview in MedTech
iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the best medical device stocks to invest in right now. Truist cut the price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $170 from $200 on April 15, reaffirming a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 […]
iRhythm Holdings Inc (IRTC) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and AI ...
iRhythm Holdings Inc (IRTC) reports a robust start to 2026 with significant revenue growth, AI advancements, and international market expansion, despite facing regulatory challenges.
Why The Narrative Around iRhythm Holdings (IRTC) Is Shifting After Valuation And DOJ Updates
The blended fair value estimate for iRhythm Holdings has been trimmed from US$199.57 to US$195.00, a modest reset that reflects updated modeling assumptions rather than a wholesale rewrite of the story. Many recent price target moves from firms such as JPMorgan and Goldman Sachs tie back to sector wide multiple compression and ongoing Department of Justice related overhangs, even as several analysts keep generally positive ratings on the stock. As you read on, you will see how these shifting...